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Background: Data comparing the incidence and pattern of intersti-
tial lung disease (ILD) in non-small cell lung cancer patients
receiving treatment with gefitinib versus erlotinib, both of which are
epidermal growth factor receptor tyrosine kinase inhibitors, are
scarce. We investigated the incidence of ILD in Japanese patients
treated with gefitinib or erlotinib.
Methods: We reviewed the clinical records of 209 patients treated
with erlotinib in 2008 (cohort A) and 330 treated with gefitinib
between 2000 and 2003 (cohort B). Toxicity within the first month
of treatment was investigated.
Results: The patients in cohort A had fewer known risk factors for
ILD (e.g., poor performance status and prior pulmonary fibrosis).
ILD was detected in two patients (1.0%) from cohort A and eight
patients (2.4%) from cohort B during the first month of treatment.
The events were graded as follows: one patient each in grades 1 and
2 (cohort A), and one, one, and six patients in grades 3, 4, and 5,
respectively (cohort B). Multivariate analysis revealed that poor
performance status and prior pulmonary fibrosis were significantly
correlated with the occurrence of ILD, but the type of epidermal
growth factor receptor tyrosine kinase inhibitor administered was
not.
Conclusion: There was a somewhat lower incidence of ILD with
erlotinib therapy than with gefitinib therapy, despite no statistically
significant difference. Patient selection based on awareness by
Japanese physicians of the risk factors for ILD, rather than the type
of agent, may explain the difference in ILD incidence between the
two treatments.
Key Words: Non-small cell lung cancer, Interstitial lung disease,
EGFR tyrosine kinase inhibitors.
(J Thorac Oncol. 2010;5: 179–184)
The recent advent of the epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs) gefitinib and er-
lotinib has revitalised interest in the treatment of advanced
non-small cell lung cancer (NSCLC), because of their unique
mechanism of action compared with cytotoxic agents. Sev-
eral phase III trials with EGFR-TKIs in relapsed patients with
NSCLC have shown the noninferiority of gefitinib to do-
cetaxel1 and a significant survival advantage of erlotinib over
best supportive care alone.2
Based on the results of a phase II trial (Iressa Dose
Evaluation in Advanced NSCLC), gefitinib was approved in
Japan for the treatment of inoperable or recurrent NSCLC in
July, 2002. However, severe pulmonary toxicity caused by
interstitial lung disease (ILD)3 was reported, and several
studies revealed that the occurrence of ILD among NSCLC
patients receiving gefitinib was 3.5 to 5.8%.4–6 A prospec-
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tive, large-cohort study recently confirmed a similar ILD
frequency (4.5%; mortality rate: 31.6%).7
The reported incidence of ILD during gefitinib treat-
ment is greater in Japanese patients than that reported outside
of Japan (1%).4–8 Several reasons have been suggested for
this difference, including differences in follow-up period, the
clinical characteristics of the study population, and the ap-
plied diagnostic criteria for ILD. Another clinically interest-
ing hypothesis is a genetic difference in response to gefitinib
between Japanese and other populations. The causes of the
difference in the incidence of ILD remain undetermined,
despite the fact that half a decade has passed since the first
report of ILD during EGFR-TKI therapy.3 Japanese oncolo-
gists and patients believe that ILD is a serious adverse event
during gefitinib treatment.
In December 2007, 5 years after the approval of ge-
fitinib by the Japanese government, erlotinib was approved.
Since then, a large number of patients have received this
agent. However, data showing the frequency of ILD among
Japanese patients receiving erlotinib are scarce. Herein, we
examined the incidence and pattern of ILD in Japanese
patients with NSCLC who were treated with gefitinib or
erlotinib monotherapy in the clinical practice setting.
PATIENTS AND METHODS
Patients and EGFR-TKI Treatment
Between November 2000 and October 2003, 365 Jap-
anese patients with NSCLC were treated with gefitinib (250
mg orally, once daily) at hospitals affiliated with the Okayama
Lung Cancer Study Group. Thirty-five patients were ex-
cluded because they were transferred to other hospitals soon
after the first prescription of gefitinib or because radiographic
reviews could not be performed. Thus, 330 patients were
available for the analysis of ILD (cohort B). Another 209
patients who received erlotinib therapy (150 mg orally, once
daily) between January and December 2008 were studied
(cohort A). Thus, a total of 539 patients were included in our
analysis. EGFR-TKI treatment was continued until disease
progression, unacceptable toxicity, or withdrawal of informed
consent by the patient. Informed consent was obtained from
each patient before EGFR-TKI treatment. This study was
approved by Institutional Review Board.
Definition of ILD and Preexisting Pulmonary
Fibrosis
The diagnostic criteria for ILD were defined as a clinical
syndrome characterized by the onset of a dry cough and hypox-
emia, accompanied by interstitial pulmonary infiltrates on a
chest radiograph or computed tomography (CT) scan or both.7–9
Preexisting pulmonary fibrosis was defined as bilateral symmet-
rical opacities having a predominantly basilar distribution, with
areas of apparently normal lung tissue and associated areas with
a honeycomb pattern. Radiation pneumonitis was excluded from
preexisting pulmonary fibrosis.
Radiologic Subclassification of ILD
The radiologic manifestations of ILD were classified
into two categories based on the consensus statement of the
American Thoracic Society9: acute interstitial pneumonia
(AIP)-like ILD and others (non-AIP–like ILD). This simple
approach was selected because the number of patients with
ILD after EGFR-TKI treatment was small, and because the
categories made it easier to apply our interpretations to
clinical practice. AIP-like manifests itself as scattered or
diffuse areas of ground-glass opacity and a thickening of the
interlobular septa with architectural distortion and traction
bronchiectasis.
Diagnosis and Confirmation of ILD During
EGFR-TKI Treatment
To investigate the efficacy and safety of EGFR-TKI
treatment, chest radiographs and CT scans were performed
periodically at each institution. Bronchoalveolar lavage or
lung biopsy was performed to detect the cause of ILD, when
possible.
To confirm the diagnosis of ILD, a radiographic review
was conducted by two pulmonologists and a diagnostic radi-
ologist, who did not treat any of the patients. Using the
available clinical information, they reviewed the findings of
the chest radiographs and CT scans before and after EGFR-
TKI treatment.
Toxicity Assessment
ILD was graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
v3.0. Toxicity was investigated during the first month after
the start of EGFR-TKI therapy, because previous studies
have shown that major adverse events related to EGFR-TKIs,
including ILD and skin rash, occur mainly within the first
month of treatment.5,7,10,11
Statistical Analysis
Statistical analyses were conducted using STATA ver-
sion 8 (College Station, TX). Multivariate analysis was per-
formed using an unconditional logistic regression model that
included potential factors linked to the occurrence of ILD.
The association between several clinical characteristics and
early toxic death was analyzed using Fisher’s exact test. p
values less than 0.05 were considered statistically significant.
RESULTS
Patient Characteristics
Table 1 summarizes the characteristics of the 539
patients. Preexisting pulmonary fibrosis was detected in 23
patients (4.3%; 3 and 20 patients in cohorts A and B,
respectively). In addition, 19 cases of idiopathic pulmonary
fibrosis, 2 cases of pulmonary fibrosis induced by collagen
diseases, and 2 cases of pneumonitis induced by prior che-
motherapeutic agents were identified.
None of the patients in cohort B received erlotinib
before gefitinib treatment, whereas 87 of the 209 cohort A
patients (42%) were given gefitinib before erlotinib therapy.
None of these 87 patients developed ILD during prior ge-
fitinib therapy.
Compared with cohort B, cohort A included more
female patients (44% versus 33%); more patients with a good
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performance status (PS) (80% versus 62%), prior thoracic
irradiation (36% versus 27%), and prior chemotherapy with
two or more regimens (79% versus 42%); and fewer patients
with prior pulmonary fibrosis (2% versus 6%).
Treatment Compliance
In cohort A (erlotinib therapy), treatment was inter-
rupted in 35 patients (17%) within the first month mainly
because of adverse events, and the treatment dose was re-
duced in 30 patients (14%). Fifty-four patients (26%) discon-
tinued erlotinib therapy within the first month because of
either disease progression (45 patients) or adverse events (10
patients: ILD in 2, skin rash in 3, infection in 2, cerebral
infarction in 2, and keratitis in 1). Similarly, in cohort B
(gefitinib therapy), treatment was discontinued prematurely
in 85 patients (26%) because of disease progression (62
patients), adverse events (16 patients: ILD in 8, nausea/
vomiting in 3, infection in 2, and skin rash, liver injury, and
fever in 1 each), patient refusal (3 patients), or unknown
causes (4 patients).
Incidence and Pattern of ILD
In cohort A, ILD was observed during the first month in
three patients. The reviewers considered 2 (1.0%) of these
cases to be compatible with drug-induced ILD, and neither
patient had a history of prior EGFR-TKI treatment. The
remaining patient was ultimately considered to be suffering
from lymphangitis. In cohort B, 13 of 330 patients were
initially thought to have developed ILD, according to the case
report forms from their institutions. However, based on the
radiologic reviews, two patients were thought to have pneu-
monia, one was identified with disease progression, one was
diagnosed with pulmonary fibrosis whose shadow was not
newly changed when compared with that before the EGFR-
TKI treatment, and no detectable abnormal shadowing was
found in one patient. Thus, eight patients (2.4%) had clini-
cally and radiographically compatible ILD during gefitinib
treatment.
The characteristics and clinical course in 10 patients are
listed in Table 2. The median time to onset of ILD after the
initiation of EGFR-TKI treatment was 13 days (range, 4–23
days). The first symptom of ILD in most patients was dys-
pnea. AIP-like pattern was detected in half of the patients.
Interestingly, the ILD events in cohort A seemed milder in
terms of subjective symptoms and radiologic findings (Figure 1),
despite the small sample size. The severity of ILD according
to the National Cancer Institute Common Terminology Cri-
teria for Adverse Events v3.0 was as follows: one patient
each with grades 1 and 2 (cohort A), and one, one, and six
patients with grades 3, 4, and 5, respectively (cohort B).
Bronchoalveolar lavage or transbronchial lung biopsy was
performed in five patients, all diagnosed pathologically as
diffuse alveolar damage. All patients were treated with ste-
roid therapy after the cessation of EGFR-TKI therapy, and
three of these patients (30%) responded to the treatment in
terms of the subjective symptoms and radiologic findings.
Risk Factors for Developing ILD
The results of univariate and multivariate analyses of
the risk factors for developing ILD are presented in Table 3.
Preexisting pulmonary fibrosis and a poor PS were identified
as independent risk factors for ILD by univariate analysis.
The type of EGFR-TKI administered did not significantly
affect the incidence of ILD, although the odds ratio favored
erlotinib therapy.
TABLE 1. Demographics of the 539 Patients
Cohort A (Erlotinib Therapy) Cohort B (Gefitinib Therapy) Total
No. of patients 209 330 539
Age, yr, median (range) 66 (35–88) 68 (29–92) 67 (29–92)
Gender
M/F 117 (56%)/92 (44%) 220 (67%)/110 (33%) 337 (63%)/202 (37%)
Performance status
0–1/2–4 167 (80%)/42 (20%) 207 (62%)/123 (8%) 374 (69%)/165 (31%)
Histologya
Ad/others 164 (79%)/44 (21%) 245 (74%)/85 (26%) 409 (76%)/129 (24%)
Disease stage
IV/others 107 (51%)/102 (49%) 182 (55%)/148 (45%) 289 (54%)/250 (46%)
Preexisting PFb
Yes/no 5 (2%)/202 (98%) 20 (6%)/310 (94%) 25 (5%)/512 (95%)
Smoking historyc
Yes/no 122 (59%)/86 (41%) 202 (62%)/123 (38%) 324 (61%)/209 (39%)
No. of prior CHa
2/2 43 (21%)/165 (79%) 191 (58%)/139 (42%) 234 (43%)/304 (57%)
Prior surgeryb
Yes/no 74 (36%)/133 (64%) 88 (27%)/242 (73%) 162 (30%)/375 (70%)
a No data available for one patient.
b No data available for two patients.
c No data available for six patients.
Ad, adenocarcinoma; PF, pulmonary fibrosis; CH, chemotherapy.
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Prognosis of 10 Patients with ILD
Six of the 10 patients (60%) who developed ILD had a
fatal outcome attributable to respiratory insufficiency caused
by the disease, within the first month after the occurrence
of ILD. Based on several clinical factors, including the type
of EGFR-TKI, gender, histology, clinical stage, presence of
preexisting pulmonary fibrosis, smoking history, PS, interval
from the initiation of gefitinib to the onset of ILD, radiologic
pattern of ILD (AIP-like versus non-AIP–like pattern), num-
ber of prior chemotherapy regimens, and age, the mortality
rate was highest in those with AIP-like shadow (100% versus
20% for with versus without AIP-like pattern; p  0.048).
None of the other clinical factors assessed were significantly
associated with early death due to ILD.
DISCUSSION
In this study, two patients (1.0%) developed ILD during
the first month of erlotinib treatment, and eight (2.4%) de-
veloped ILD during the first month of gefitinib therapy.
Preexisting pulmonary fibrosis and a poor PS were signifi-
cantly associated with the occurrence of ILD but not the type
of EGFR-TKI.
Although there was no statistically significant differ-
ence in the incidence of ILD attributable to gefitinib and
erlotinib, the trend toward a lower incidence for erlotinib is of
potential clinical interest. This may be attributable to patient
selection. Regarding preexisting pulmonary fibrosis as a risk
factor for ILD,4–6,12,13 patients diagnosed with pulmonary
fibrosis were more likely to be in cohort B than in cohort A
(Table 1). Indeed, stratified by the presence of prior pulmo-
nary fibrosis in cohort B, the incidence of ILD in patients
without prior pulmonary fibrosis (3 of 310; 1.0%) was much
lower than that in patients with prior pulmonary fibrosis (5
of 20; 25.0%). It is possible that awareness of this risk
factor has risen among Japanese physicians, and that as a
result, physicians tend to view EGFR-TKI therapy as being
unsuitable for patients with preexisting pulmonary fibrosis.
This could explain the reduced incidence of ILD in cohort
A. In contrast, the 60% mortality is somewhat higher than
has been reported in the previous literature.6 It is possible
that mild disease was underrecognized in this analysis or
overdiagnosed in other study.
Notably, about half of the patients in cohort A had
previously received gefitinib therapy, and none had devel-
oped ILD during gefitinib treatment. Thus, it may be that
those patients who were unlikely to develop ILD were un-
knowingly selected for treatment with erlotinib monotherapy,
resulting in selection bias in our cohorts. This could explain
the difference in ILD incidence between the cohorts. In any
case, patient selection seems to be important in EGFR-TKI
therapy in terms of safety.
Patients with a poor PS or preexisting pulmonary
fibrosis had a higher incidence of ILD in the current cohort
study (Table 3). A previous Japanese study also showed a
higher incidence of ILD emergence during gefitinib ther-
apy in patients with a poor PS (5.1%) or preexisting
pulmonary fibrosis (13.9%).6 In contrast, European and
Canadian studies revealed a lower frequency of ILD eventsTA
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TABLE 3. Risk Factors for the Occurrence of Interstitial Lung Disease
No. of Patients Univariate
Analysisa
p
Multivariate Analysisb
Evaluable With ILD (%) OR (95% CI) p
Total 539 10 (1.9)
Type of EGFR tyrosine kinase inhibitor
Erlotinib 209 2 (1.0) 0.330 0.711 (0.105–4.818) 0.727
Gefitinib 330 8 (2.4) 1
Preexisting pulmonary fibrosisc
Yes 24 6 (25.0) 0.001 41.054 (9.104–185.128) 0.001
No 513 4 (1.0) 1
Performance status
0–1 374 3 (1.0) 0.011 0.180 (0.035–0.935) 0.041
2–4 165 7 (4.2) 1
Prior surgeryc
Yes 162 3 (1.9) 0.999 1.256 (0.239–6.619) 0.788
No 375 7 (1.9) 1
Smoking statusd
Ever 324 8 (2.5) 0.329 0.673 (0.057–7.876) 0.752
Never 209 2 (1.0) 1
Gender
Male 337 8 (2.4) 0.334 3.024 (0.258–35.487) 0.378
Female 202 2 (1.0) 1
Histologye
Ad 409 8 (2.0) 0.999 1.898 (0.315–11.435) 0.378
Others 129 2 (1.6) 1
No. of prior chemotherapy regimense
2 234 6 (2.6) 0.344 0.993 (0.211–4.666) 0.993
2 304 4 (1.3) 1
a Fisher’s exact test.
b Logistic regression model.
c No data available for two patients.
d No data available for six patients.
e No data available for one patient.
ILD, interstitial lung disease; OR, odds ratio; CI, confidence interval; Ad, adenocarcinoma.
FIGURE 1. Representative radiograph of interstitial
lung disease during the erlotinib treatment.
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during EGFR-TKI therapy in NSCLC patients, even in
those with a poor PS.14,15 The difference in the incidence
of ILD between these Asian and non-Asian populations
can probably not be accounted for by patient selection (i.e.,
differences in clinical characteristics) but may be partially
explained by genetic differences in the response to EGFR-
TKIs between the two population. As a relevant clinical
issue, there was an ethnic difference in the degree of
toxicity between Japanese and American patients given
carboplatin and paclitaxel therapy for NSCLC.16 In addi-
tion, a phase II study of uracil/tegafur and leucovorin in
previously untreated metastatic colorectal cancer patients
demonstrated that the incidence of diarrhea and nausea/
vomiting was higher in American patients than in Japanese
patients.17 Further work is needed to determine the mech-
anism of ILD and its ethnic differences.
The quality of our study might have been affected by
the fact that there was a big difference in time frame (2008
versus 2000–2003 in cohort A versus B) and by the lack of
recent gefitinib data. In addition, our analysis was based on a
retrospective review with an unplanned analysis, and there
was no uniform procedure for patient follow-up. The patient
characteristics were also not identical between the cohorts,
although we did our best to adjust for heterogeneity in the
subgroups using multivariate analysis. In addition, we ana-
lyzed the adverse events that occurred only during the first
month of therapy and not long-term data; for instance, this
would affect the difference in the ILD incidence between our
and other series.18 Thus, our conclusions should be inter-
preted cautiously.
In conclusion, in our setting, the type of EGFR-TKI did
not affect the incidence of ILD, although the incidence was
somewhat lower during erlotinib therapy than during gefitinib
therapy. Furthermore, the grade of ILD was less severe in
cohort A. These results may be due in part to patient selec-
tion, given the recent awareness by Japanese physicians of
the risk factors for ILD during EGFR-TKI treatment.
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